A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 54
Summary
- Conditions
- Advanced Cancer
- Breast Cancer
- Cancer of Stomach
- Colo-rectal Cancer
- Gastric Cancer
- Pancreatic Cancer
- Prostate Cancer Metastatic
- Solid Carcinoma
- Solid Carcinoma of Stomach
- Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03129139
- Collaborators
- Translational Drug Development
- Investigators
- Study Director: Jordan Jacobs, MBA Translational Drug Development
Get Well Soon